Compare BH & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BH | KALV |
|---|---|---|
| Founded | 1934 | N/A |
| Country | United States | United States |
| Employees | 2359 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.1M | 1.0B |
| IPO Year | N/A | 2014 |
| Metric | BH | KALV |
|---|---|---|
| Price | $271.26 | $26.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.60 |
| AVG Volume (30 Days) | 63.0K | ★ 4.5M |
| Earning Date | 05-04-2026 | 07-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | N/A | $185.42 |
| Revenue Next Year | N/A | $59.23 |
| P/E Ratio | $597.67 | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $230.12 | $9.83 |
| 52 Week High | $483.60 | $26.85 |
| Indicator | BH | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 41.04 | 74.83 |
| Support Level | $269.96 | $14.56 |
| Resistance Level | $321.70 | N/A |
| Average True Range (ATR) | 17.13 | 0.15 |
| MACD | -2.89 | 0.01 |
| Stochastic Oscillator | 44.58 | 98.60 |
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, and Oil and Gas Operations. Its restaurant operations include Steak n Shake and Western Sizzlin. Its insurance operations include First Guard, Southern Pioneer, and Biglari Reinsurance. Oil and gas operations include Southern Oil and Abraxas Petroleum. The company also reports segment information for Maxim. The majority of revenue is derived from the Restaurant Operations Segment.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.